<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01208155</url>
  </required_header>
  <id_info>
    <org_study_id>D4300C00016</org_study_id>
    <nct_id>NCT01208155</nct_id>
  </id_info>
  <brief_title>Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets</brief_title>
  <official_title>An Open-label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of 4 Different Fostamatinib Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study in healthy males to assess bioavailability of 4 different fostamatinib tablets
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 50 mg tablets versus 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 1 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 50 mg tablets versus 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 2 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 50 mg tablets versus 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 3 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 50 mg tablets versus 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 4 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 1 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 2 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 3 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative bioavailability of R406 when fostamatinib is administered as 3 different 100 mg tablet batches (assessment will include but is not limited to: plasma R406 AUC, Cmax )</measure>
    <time_frame>Daily during Treatment Period 4 until 96 hours post dose of each treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To examine the safety and tolerability of fostamatinib 50 mg and 100 mg tablet batches The safety endpoints will include: adverse event monitoring, vital signs, physical examinations, clinical laboratory tests, ECGs.</measure>
    <time_frame>Screening, throughout the 4 treatment periods, and follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Bioavailability</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 50 mg tablet x 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 100 mg tablet (batch 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 100 mg tablet (batch 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fostamatinib 100 mg tablet (batch 4)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 50 mg x 2, single dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 100 mg Batch 1, single dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 100 mg Batch 2, single dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Oral tablets, 100 mg Batch 3, single dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight of at least 50 kg and body mass index (BMI) between 18.0 and 35.0 kg/m2
             inclusive

          -  Volunteers must be willing to use barrier contraception ie, condoms, from the Day 1 of
             Treatment Period 1 until 2 weeks after the final dosing of the investigational product
             (IP)

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder

          -  History or presence of GI, hepatic, or renal disease or any other condition known to
             interfere with absorption, distribution, metabolism, or excretion of drugs (except for
             cholecystectomy)

          -  Any clinically significant illness, medical/surgical procedure or trauma within 4
             weeks of the first administration of drug

          -  Volunteers who smoke more than 5 cigarettes or the equivalent in tobacco per day

          -  Any clinically significant abnormalities in clinical chemistry, hematology or
             urinalysis results as judged by the Investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Layton, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos Prendes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2010</study_first_submitted>
  <study_first_submitted_qc>September 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2010</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Fostamatinib</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

